We were thrilled to see new clinical data on SimplyFi presented at the congress. The poster highlighted results from the prospective, multicenter IDEAL 2B trial, conducted across three European centers — and the early outcomes are very promising.
The study demonstrated the feasibility, safety, and encouraging short-term functional improvements in patients with fecal incontinence following implantation of the SimplyFi band. Notable benefits included reductions in St. Mark’s scores and improvements in FIQL scores, offering a fresh, meaningful option for patients with limited treatment pathways.
While the study is still ongoing, these initial findings further strengthen confidence in SimplyFi’s role as an innovative solution for managing fecal incontinence.
We appreciate the clinical teams for presenting their work at ECC and helping advance progress in colorectal care.
